Influence of Achieved Low-Density Lipoprotein Cholesterol Level With Atorvastatin Therapy on Stabilization of Coronary Plaques: Sub-Analysis of the TWINS Study

Background: Previously the stabilization of coronary plaque with atorvastatin was demonstrated in the TWINS (evaluaTion With simultaneous angIoscopy and iNtravascular ultraSound) study. The influence of the low-density lipoprotein cholesterol (LDL-C) level on plaque stabilization was analyzed. Metho...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Circulation Journal 2012, Vol.76(5), pp.1197-1202
Hauptverfasser:	Okada, Katsuki, Ueda, Yasunori, Takayama, Tadateru, Honye, Junko, Komatsu, Sei, Yamaguchi, Osamu, Li, Yuxin, Yajima, Junji, Takazawa, Kenji, Nanto, Shinsuke, Saito, Satoshi, Hirayama, Atsushi, Kodama, Kazuhisa
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Angioscopy Anticholesteremic Agents - administration & dosage Atorvastatin Cholesterol, LDL - blood Coronary Angiography Coronary Artery Disease - blood Coronary Artery Disease - diagnostic imaging Coronary Artery Disease - drug therapy Coronary Vessels Female Heptanoic Acids - administration & dosage Humans Hypercholesterolemia - blood Hypercholesterolemia - diagnostic imaging Hypercholesterolemia - drug therapy Male Middle Aged Plaque, Atherosclerotic - blood Plaque, Atherosclerotic - diagnostic imaging Plaque, Atherosclerotic - drug therapy Pyrroles - administration & dosage Stabilization of coronary plaque Ultrasonography, Interventional Yellow plaque
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Background: Previously the stabilization of coronary plaque with atorvastatin was demonstrated in the TWINS (evaluaTion With simultaneous angIoscopy and iNtravascular ultraSound) study. The influence of the low-density lipoprotein cholesterol (LDL-C) level on plaque stabilization was analyzed. Methods and Results: Patients (n=29) with hypercholesterolemia and coronary artery disease (CAD) were analyzed. They received atorvastatin (10-20mg/day) for 80 weeks and were divided into low (
ISSN:	1346-9843 1347-4820
DOI:	10.1253/circj.CJ-11-0966